OncoMatch/Clinical Trials/NCT04301765
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Is NCT04301765 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies testosterone 1.62% gel for hypogonadism, male.
Treatment: testosterone 1.62% gel — This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: chemotherapy
have received or are receiving chemo- and/or radiation therapy
Must have received: radiation therapy
have received or are receiving chemo- and/or radiation therapy
Cannot have received: anabolic agents (testosterone, DHEA, growth hormone)
Use of anabolic agents (testosterone, DHEA, growth hormone) within the past 6 months
Lab requirements
Blood counts
Hematocrit >48% [excluded]
Hematocrit >48%, serum creatinine >2.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Georgia Cancer Center at Augusta University · Augusta, Georgia
- Brigham and Women's Hospital · Boston, Massachusetts
- Veterans Affairs Puget Sound Health Care System · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify